INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
|
|
- Damon Doyle
- 6 years ago
- Views:
Transcription
1 INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program University of Miami Miller School of Medicine April 8, 2016
2 DISCLOSURES Advisory Boards: Boehringer Ingelheim, Genentech, Mesoblast Research Grants: Genentech; Lester and Sue Smith Foundation, Marcus Foundation; NIH
3 74-YEAR-OLD MALE EX-SMOKER WITH COUGH & DYSPNEA History: 12 months ago developed productive cough and shortness of breath Referred to pulmonologist with abnormal CXR and had HRCT of chest Hospitalized 14 months later with increased dyspnea and hypoxemia treated with antibiotics and steroids Dyspnea with ADLs Since discharge, requires continuous oxygen therapy Frequent heartburn Reports poor sleep, snoring and daytime fatigue Past Medical/Family/Social History +HTN, Hyperlipidemia Family history of CAD, Former 30 pack year smoker Exam 140/66, 86, 22, SpO2 90% at rest on RA; BMI 27 Bibasilar inspiratory crackles, no wheeze No peripheral edema or signs of CHF
4 74-YEAR-OLD MALE EX-SMOKER WITH COUGH & DYSPNEA FEV 1 FVC FEV 1 /FVC DL CO February (84%) 2.80 (64%) (34%)
5 HRCT 14 MONTHS LATER
6 IDIOPATHIC PULMONARY FIBROSIS Normal Lung Usual Interstitial Pneumonia
7 WHERE DOES IPF FIT IN THE CONTEXT OF THE ILDS? The most common ILD: 42,000 new cases per year Definition of IPF: Specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause Occurring primarily in males above the age of 55 Limited to the lungs 80% are ex-smokers Raghu G, et al, and the ATS/ERS/JRS/ALAT Committee on IPF. Am J Respir Crit Care Med. 2011;183:
8 HISTORICAL CLASSIFICATION OF INTERSTITIAL LUNG DISEASES MAJOR IIPs Sarcoidosis Hypersensitivity Pneumonitis (EAA) 1970s Idiopathic IPs Heterogeneous group that included a number of diseases IPF DIP AIP NSIP RB- ILD 2016 Cellular Asbestosis LAM BML LG Rare IIPs COP Fibrotic Unclassifiable IIPs Adapted from Ryu JH, et al. Mayo Clin Proc. 1998;73: Adapted from ATS/ERS. Am J Respir Crit Care Med. 2013;188: Pleuroparenchymal Fibroelastosis ILIP
9 IPF IS THE MOST COMMON IDIOPATHIC INTERSTITIAL PNEUMONIA Interstitial lung disease (ILD) ILD of known cause Idiopathic interstitial pneumonias Granulomatous ILD Other forms of ILD Major idiopathic interstitial pneumonias Rare idiopathic interstitial pneumonias Unclassifiable idiopathic interstitial pneumonias Desquamative interstitial pneumonia Idiopathic pulmonary fibrosis (IPF) Idiopathic lymphoid interstitial pneumonia Cryptogenic organizing pneumonia Idiopathic nonspecific interstitial pneumonia Idiopathic pleuroparenchymal fibroelastosis Acute interstitial pneumonia Respiratory bronchiolitis-interstitial lung disease Travis WD et al. Am J Respir Crit Care Med. 2013;188(6):
10 DISTINGUISHING DYSPNEA Disease Prevalence, United States IPF 1 136,170 Heart failure million COPD million Million 1. Raghu G, 2013; 2. Go AS, et al. Circulation. 2013;127:e6 e Wheaton AG, et al. MMWR Morb Mortal Wkly Rep. 2015;64:
11 Percentage of Patients THE INCIDENCE OF IPF INCREASES WITH AGE Age of Incident Medicare Patients with IPF at Diagnosis in Raghu G et al. Lancet Respir Med. Appendix. 2014;2:
12 RISK FACTORS/LOCATION OF IPF IN US Age Male sex Highest Lowest Medium Hispanic ethnicity Geography Raghu G, et al. Lancet Respir Med. 2014;2(7):
13 SURVIVAL IN IPF IS WORSE THAN MOST CANCERS 5-Year Survival Rate, a % IPF survival is comparable to that of lung cancer Lung Cancer IPF Ovarian Cancer PAH Colorectal Cancer Breast Cancer
14 Months PATIENTS WITH IPF ARE OFTEN MISDIAGNOSED Disease Onset 1-2 Years (average) Diagnosis Patients are often misdiagnosed with bronchitis, asthma, COPD, emphysema, or heart disease Duration of Time from Disease Onset to Diagnosis Cellular NSIP Fibrotic NSIP IPF
15 PROGRESSION OF IPF Normal Progressive destruction of lung architecture 5-year survival rate from diagnosis = 20 to 40% Age of onset : 2/3 over age 60
16 Respiratory Function/Symptoms IPF: A DISEASE WITH AN UNPREDICTABLE CLINICAL COURSE Slowly progressive Rapidly progressive Acute exacerbations Years Kim DS, et al. Proc Am Thorac Soc. 2006; 3:
17 P e r c e n t s u r v iv a l Percent Survival P e r c e n t s u r v iv a l DIFFUSING CAPACITY PREDICTS SURVIVAL IN IPF DL co 50% DL co 35-49% Dl co < 35% D L c o = D> 5L 0 c % o = > 5 0 % D L c o 3D5-4 L c9 o% % D L c o < D 3 5 L % c o < 3 5 % P= M o4n 8th s M o n th s Months Nathan SD, et al. Chest. 2011;140:
18 Percent Survival P e r c e n t s u r v iv a l P e r c e n t s u r v iv a l FVC PREDICTS SURVIVAL IN IPF FVC 70% FVC 55-69% FVC < 55% F V C > o r= F 7V 0 C % > o r= 7 0 % F V C F V9 C % % F V C < 5 5 F % V C < 5 5 % P= M o 4n 8th s Months M o n th s Nathan SD, et al. Chest. 2011;140:
19 6MWT: PARAMETERS PREDICT SURVIVAL IN IPF Baseline 6MWT distance 6MWT distance at 24 weeks du Bois RM, et al. Eur Respir J. 2014;43(5): Swigris JJ, et al. Chest. 2009;136:
20 Survival GERD TREATMENT AND SURVIVAL Time to Event (days) Lee JS, et al. Am J Respir Crit Care Med. 2011;184(12):
21 OBSTRUCTIVE SLEEP APNEA IS COMMON IN IPF 55 subjects with IPF Sleep apnea evaluation Epworth Sleepiness Scale Sleep Apnea Scale of Sleep Disorders Nocturnal polysomnography Findings that did not correlate with OSA Spirometry Lung volume DLCO ESS 68% No OSA AHI 5/h 12% Moderate/Severe AHI > 15 events/h 20% Mild AHI 5 15/h AHI: apnea-hypopnea index Lancaster LH, et al. Chest. 2009;136:
22 DIAGNOSTIC ALGORITHM FOR IPF Patient presents with suspected ILD Detailed history Physical exam PFT Clinical presentation: Typically affects adults >50 years of age Chronic exertional dyspnea Dry, nonproductive cough Crackles or rales on auscultation Digital clubbing Adapted from Raghu G et al. 1 CTD, connective tissue disorder; MDD, multidisciplinary discussion; PFT, pulmonary function testing. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Flaherty KR, Khanna D. Thorax. 2014;69(3):
23 Diagnostic Algorithm for IPF Yes Patient presents with suspected ILD Detailed history Physical exam PFT Identifiable cause of ILD? No Serologic testing to exclude CTD Exposures (environmental, occupational, pets) 1 Skin, joint, or muscle findings including arthritis, pleurisy, skin thickening, and Raynaud s phenomenon may indicate a connective tissue disorder 1 Not IPF Adapted from Raghu G et al. 1 CTD, connective tissue disorder; MDD, multidisciplinary discussion; PFT, pulmonary function testing. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Flaherty KR, Khanna D. Thorax. 2014;69(3):
24 Diagnostic Algorithm for IPF Patient presents with suspected ILD Detailed history Physical exam PFT Yes Positive Identifiable cause of ILD? No Serologic testing to exclude CTD Not IPF Adapted from Raghu G et al. 1 CTD, connective tissue disorder; MDD, multidisciplinary discussion; PFT, pulmonary function testing. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Flaherty KR, Khanna D. Thorax. 2014;69(3):
25 Diagnostic Algorithm for IPF Patient presents with suspected ILD Detailed history Physical exam PFT HRCT is critical to making an accurate diagnosis of IPF 1 UIP Possible UIP Inconsistent with UIP Yes Positive Identifiable cause of ILD? No Serologic testing to exclude CTD Negative HRCT Not IPF Adapted from Raghu G et al. 1 CTD, connective tissue disorder; MDD, multidisciplinary discussion; PFT, pulmonary function testing. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Flaherty KR, Khanna D. Thorax. 2014;69(3):
26 Diagnostic Algorithm for IPF Yes Positive Patient presents with suspected ILD Detailed history Physical exam PFT Identifiable cause of ILD? No Serologic testing to exclude CTD Negative HRCT HRCT is critical to making an accurate diagnosis of IPF 1 o o o UIP Definite UIP Possible UIP Inconsistent with UIP UIP Image courtesy of and used with permission from Jonathan Goldin, MD, PhD. Not IPF IPF Adapted from Raghu G et al. 1 CTD, connective tissue disorder; MDD, multidisciplinary discussion; PFT, pulmonary function testing. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Flaherty KR, Khanna D. Thorax. 2014;69(3):
27 Diagnostic Algorithm for IPF Patient presents with suspected ILD Detailed history Physical exam PFT Not UIP Yes Positive Not UIP Identifiable cause of ILD? No Serologic testing to exclude CTD Negative HRCT Image courtesy of and used with permission from Jonathan Goldin, MD, PhD. Definite UIP Not IPF IPF Adapted from Raghu G et al. 1 CTD, connective tissue disorder; MDD, multidisciplinary discussion; PFT, pulmonary function testing. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Flaherty KR, Khanna D. Thorax. 2014;69(3):
28 Diagnostic Algorithm for IPF Patient presents with suspected ILD Detailed history Physical exam PFT Not UIP Yes Positive Not UIP Identifiable cause of ILD? No Serologic testing to exclude CTD Negative HRCT Possible UIP Surgical lung biopsy Possible UIP Image courtesy of and used with permission from Jonathan Goldin, MD, PhD. Definite UIP Not IPF IPF Adapted from Raghu G et al. 1 CTD, connective tissue disorder; MDD, multidisciplinary discussion; PFT, pulmonary function testing. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Flaherty KR, Khanna D. Thorax. 2014;69(3):
29 Diagnostic Algorithm for IPF Patient presents with suspected ILD Detailed history Physical exam PFT Not UIP Yes Positive Not UIP Not UIP Identifiable cause of ILD? No Serologic testing to exclude CTD Negative HRCT Possible UIP Surgical lung biopsy Possible UIP Image used with permission from the American Thoracic Society Raghu G et al. 1 Definite UIP Not IPF IPF Adapted from Raghu G et al. 1 CTD, connective tissue disorder; MDD, multidisciplinary discussion; PFT, pulmonary function testing. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Flaherty KR, Khanna D. Thorax. 2014;69(3):
30 Diagnostic Algorithm for IPF Patient presents with suspected ILD Detailed history Physical exam PFT Not UIP Yes Positive Not UIP Not UIP Identifiable cause of ILD? No Serologic testing to exclude CTD Negative HRCT Possible UIP Surgical lung biopsy Image used with permission from the American Thoracic Society Raghu G et al. 1 Definite UIP Not IPF Not UIP UIP/Probable UIP UIP MDD IPF Adapted from Raghu G et al. 1 CTD, connective tissue disorder; MDD, multidisciplinary discussion; PFT, pulmonary function testing. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Flaherty KR, Khanna D. Thorax. 2014;69(3):
31 PATHOGENESIS OF IPF Epithelial cell injury and activation INJURY Epithelial apoptosis Progressive fibrosis and impaired reepithelialization Wound clot Fibroblast migration and proliferation Basement membrane disruption Myofibroblast accumulation Angiogenesis Ahluwalia N, et al. Am J Respir Crit Care Med. 2014;190(8):
32 PAST NEGATIVE CLINICAL TRIALS IN IPF 2000-PRESENT Trial n Primary Endpoint Result Interferon-beta (1999) 167 Progression-free survival time Negative Interferon-gamma (GIPF-001) 330 Progression-free survival Negative Interferon-gamma (Inspire) 826 Survival time Negative Pirfenidone (CAPACITY 1) 344 Change in FVC Negative Etanercept 100 Change in DL co, FVC Negative Imatinib Mesylate 120 Progression-free survival Negative Bosentan (BUILD 1 and 2) 132 Change in 6MW Negative Bosentan (BUILD 3) 390 Progression-free survival time Negative Sildenafil (STEP) 29 Change in 6MWD, Borg dyspnea index Negative Ambrisentan (Artemis-IPF) 478 Progression-free survival Stopped Ambrisentan (Artemis-PH) 50 6MWD Stopped Everolimus Noth I et al. Am J Respir Crit Care Med ;186: Progression Negative
33 PHARMACOLOGIC APPROACHES FDA APPROVED IN OCTOBER 2014 Two drugs: Nintedanib and Pirfenidone Effective in slowing functional decline and disease progression Current evidence supports timely diagnosis and administration of treatment Neither drug cures IPF
34 MSCS: A UNIQUE IMMUNOPRIVILEGED CELL Williams and Hare. Circ Res 2011; 109:923-40
35 YOUNG MSCS PREVENT LUNG FIBROSIS Tashiro J., et al. Transl Res Dec;166(6):554-67
36
37 PRELIMINARY SAFETY RESULTS FIRST IN MAN FDA APPROVED CLINICAL TRIAL COMPLETED DECEMBER 2015 No infusion related adverse events Most common adverse event was bronchitis Promising exploratory endpoints: Walk test distance Lung Function Oxygen usage
38 KEY POINTS: WORK-UP SHORTNESS OF BREATH REFER EARLY TO SPECIALIST
39 March 14, 2016
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationInterstitial Lung Disease (ILD)
Interstitial Lung Disease (ILD) ILD comprises more than 130 distinct disorders Characterized by cellular proliferation, cellular infiltration, and/or fibrosis of the lung parenchyma not due to infection
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationINHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)
THE INCREASE STUDY INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) Peter Smith, PharmD Senior Director Product Development, United Therapeutics Corporation 2 SAFE
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationChallenges in Pulmonary and Critical Care: 2018
Challenges in Pulmonary and Critical Care: 2018 Interstitial Lung Disease: Evolving Our Understanding of a Deadly Disease 1 Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical Care Medicine
More informationNintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationManagement of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures
Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationInterstitial Lung Disease ILD: Definition
Interstitial Lung Disease 2007 Paul F. Simonelli,, MD, PhD, FCCP Clinical Director Center for Interstitial Lung Disease Columbia University Medical Center 1. ILD is not one disorder ILD: Definition 2.
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationDr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham
Dr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham Types of Questions you Will Be Asked Rhetorical Participatory Disclosure of Relevant Financial
More informationWim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art.
nterstitial ungdiseases euven Department of pneumology Unit for interstitial lung diseases University Hospitals Leuven March 12 th 2015 Interstitial lung diseases state of the art Treatment of idiopathic
More information9/12/18. Emerging Challenges in Primary Care: Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis
Emerging Challenges in Primary Care: 2018 Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationNew Therapies and Trials in IPF
Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: New Therapies and Trials in IPF Talmadge E. King, Jr., M.D. Julius R. Krevans
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationStrategies for Updated Treatment Options for IPF
Strategies for Updated Treatment Options for IPF Paul W. Noble, MD Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine Professor and Chair Department of Medicine Director, Women's Guild
More informationUnpaid scientific collaborator & advisor with Veracyte, Inc.
Diagnosis and Classification of Idiopathic Interstitial Pneumonias: Role of Histopathology in the Golden Age of Consensus Jeffrey L. Myers, M.D. A. James French Professor of Diagnostic Pathology Vice Chair
More informationNew Horizons The Future of IPF and ILD
New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationGuidelines for Diagnosis and Treatment of IPF
Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease
More informationRegulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.05 Subject: Ofev Page: 1 of 5 Last Review Date: March 17, 2017 Ofev Description Ofev (nintedanib)
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationIdiopathic Pulmonary Fibrosis: State-of-the-Art Evaluation and Management: Comorbidities in IPF
Idiopathic Pulmonary Fibrosis: State-of-the-Art Evaluation and Management: Comorbidities in IPF Steven D. Nathan, MBBCh, FCCP Advanced Lung Disease &Transplant Program Inova Fairfax Hospital Professor
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationIdiopathic Pulmonary Fibrosis Treatable and Not Idiopathic
Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic Brett Ley, MD University of California San Francisco CTS 1/26/18 Disclosures Speaker s bureau honorarium from Genentech (makers of pirfenidone)
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)
More informationIPF: Epidemiologia e stato dell arte
IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic
More informationCurrent diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM
Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University
More informationNAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis
NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis Mark J Rumbak, MD Division Director Pulmonary, Critical Care and Sleep Medicine Morsani College of Medicine University of South Florida, Tampa
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationIPF - Inquadramento clinico
IPF - Inquadramento clinico Sergio Harari Unità Operativa di Pneumologia UTIR Servizio di Fisiopat. Resp. e Emodinamica Polmonare Ospedale S. Giuseppe, Milano Clinical Classification Diffuse parenchimal
More informationDisclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease
Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor
More informationDiagnosing ILD. What is important in 2016? Chris Grainge
Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a
More informationCOI: no conflicts of interest to declare
Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion
More informationTriennial Pulmonary Workshop 2012
Triennial Pulmonary Workshop 2012 Rod Richie, M.D., DBIM Medical Director Texas Life Insurance Company, Waco, TX EMSI, Waco, TX Lisa Papazian, M.D., DBIM Assistant Vice President and Medical Director Sun
More informationChallenges in the classification of fibrotic ILD
Review SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; Suppl. 1: 4-9 Mattioli 1885 Challenges in the classification of fibrotic ILD Elisabeth Bendstrup 1, Toby M. Maher 2, Effrosyni D. Manali
More informationSummary: Key Learning Points, Clinical Strategies, and Future Directions
Summary: Key Learning Points, Clinical Strategies, and Future Directions Introduction Idiopathic pulmonary fibrosis (IPF), a peripheral lobular fibrosis of unknown cause, is a chronic, progressive lung
More informationMultidisciplinary Diagnosis in Action: Challenging Case Presentations
Multidisciplinary Diagnosis in Action: Challenging Case Presentations Interstitial Lung Disease: Advances in Diagnosis and Management UCSF CME November 8, 2014 Case 1 69 yo M 3 year history of intermittent
More informationUsual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
More informationDIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?
NIHR Southampton Respiratory Biomedical Research Unit DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? Fibrosing Interstitial Lung Diseases CPFS/WASOG/AIPO/ERS
More informationTherapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic
Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationIDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management
IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management An ATS Pocket Publication This publication was produced in collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. GUIDELINES
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationIdiopathic pulmonary fibrosis
Pharmacologic Treatments for Idiopathic Pulmonary Fibrosis This chronic disease has historically lacked an effective treatment option, but the FDA recently approved two: pirfenidone and nintedanib. This
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationEpidemiology and classification of smoking related interstitial lung diseases
Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationUIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!
UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France CASE OVERVIEW This case highlights how a usual
More informationDiffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious
Focused Issue of This Month Diagnostic Approaches to Diffuse Interstitial Lung Diseases Dong Soon Kim, MD Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine E -
More informationManish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationRole of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study
36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationOctober 30, The Westin Princeton at Forrestal Village 201 Village Boulevard Princeton, NJ Marilyn Glassberg Csete, MD FACP, FCCP
October 3, 215 The Westin Princeton at Forrestal Village 21 Village Boulevard Princeton, NJ 854 Marilyn Glassberg Csete, MD FACP, FCCP Professor of Medicine, Surgery, and Pediatrics at the University of
More informationAn earlier and more confident diagnosis of idiopathic pulmonary fibrosis
Eur Respir Rev 2012; 21: 124, 141 146 DOI: 10.1183/09059180.00000812 CopyrightßERS 2012 REVIEW: IPF An earlier and more confident diagnosis of idiopathic pulmonary fibrosis Roland M. du Bois ABSTRACT:
More informationOFEV MEDIA BACKGROUNDER
OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small
More informationPulmonary Pearls. Medical Pearls. Case 1: Case 1 (cont.): Case 1: What is the Most Likely Diagnosis? Case 1 (cont.):
Pulmonary Pearls Christopher H. Fanta, MD Pulmonary and Critical Care Division Brigham and Women s Hospital Partners Asthma Center Harvard Medical School Medical Pearls Definition: Medical fact that is
More informationUIP Possibile e Probabile
UIP Possibile e Probabile Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale San Giuseppe - Milano Current definition of IPF IPF is a distinct type
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationManagement of Idiopathic Pulmonary Fibrosis
Management of Idiopathic Pulmonary Fibrosis Robert Hallowell, M.D. December 22, 2015 Disclosures No financial disclosures What causes IPF? +? VEGF-R Airspace lining TNFa Fibrocytes PDGF Fibroblasts IL-1
More informationChallenges in Pulmonary and Critical Care 2017
Challenges in Pulmonary and Critical Care 2017 Idiopathic Pulmonary Fibrosis: New Advances in Therapy Outcome Report: Boehringer Ingelheim Grant # ME201722329 February 2, 2018 Level 1 (Participation) Practice
More informationOut of proportion pulmonary hypertension
IPF the missing link Out of proportion pulmonary hypertension Rome 29-30 May 2015 Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale San Giuseppe -
More informationMedicine. Auscultation of Velcro Crackles is Associated With Usual Interstitial Pneumonia
Medicine OBSERVATIONAL STUDY Auscultation of is Associated With Usual Interstitial Pneumonia Jacobo Sellarés, MD, Fernanda Hernández-González, MD, Carmen M Lucena, MD, Marina Paradela, MD, Pilar Brito-Zerón,
More informationWhat do pulmonary function tests tell you?
Pulmonary Function Testing Michael Wert, MD Assistant Professor Clinical Department of Internal Medicine Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical
More informationTimely Topics in Pulmonary Medicine
Disclosures Timely Topics in Pulmonary Medicine I have nothing to disclose! Lorriana Leard, MD Associate Professor of Clinical Medicine Chief of Clinical Operations UCSF Pulmonary, Critical Care, Allergy
More informationPerspectives ILD Diagnosis and Treatment in 5-10 years
Perspectives ILD Diagnosis and Treatment in 5-10 years Brett Ley, MD Department of Medicine The (Near) Future of ILD Diagnosis and Treatment 1. Combination therapy for Idiopathic Pulmonary Fibrosis 2.
More informationGuide to Clinical Management of Idiopathic Pulmonary Fibrosis
Guide to Clinical Management of Idiopathic Pulmonary Fibrosis Steven D Nathan A Whitney Brown Christopher S King Guide to Clinical Management of Idiopathic Pulmonary Fibrosis Steven D Nathan Inova Fairfax
More informationESBRIET (pirfenidone) oral capsule and oral tablet OFEV (nintedanib) oral capsule
OFEV (nintedanib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationPre-op Clinical Triad - Pulmonary. Sammy Pedram, MD FCCP Assistant Professor of Medicine Pulmonary & Critical Care Medicine March 16, 2018
Pre-op Clinical Triad - Pulmonary Sammy Pedram, MD FCCP Assistant Professor of Medicine Pulmonary & Critical Care Medicine March 16, 2018 Disclosures none Case Mr. G is a 64 year-old man who presents to
More informationA primary care approach to interstitial lung disease. When to suspect idiopathic pulmonary fibrosis. Jonathan Ilowite, MD
A primary care approach to interstitial lung disease When to suspect idiopathic pulmonary fibrosis Jonathan Ilowite, MD This Special Report was supported by PC-US-102697 01/18 INTRODUCTION / OVERVIEW A
More informationCome gestire le comorbidità e il follow-up
Come gestire le comorbidità e il follow-up Antonella Caminati U.O. di Pneumologia e Terapia Semi Intensiva Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Osp. San Giuseppe - MultiMedica,
More informationCombined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases
CASE REPORT Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases Nobuhiko Nagata 1, Kentaro Watanabe 2, Michihiro Yoshimi 3, Hiroshi Okabayashi 4, Katsuo Sueishi 5, Kentaro
More informationINTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf
Indep Rev Jul-Dec 2018;20(7-12) Dr. Zulqarnain Ashraf IR-653 Abstract: ILD is a group of diseases affect interstitium of the lung. Repeated insult to the lung cause the interstitium to be damaged. Similarly
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationCurrent Management of IPF and. Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine
Current Management of IPF and fibrosing ILDs Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine Introduction Idiopathic pulmonary fibrosis clinical course is variable and long term survival is poor Therapy
More informationNINTEDANIB MEDIA BACKGROUNDER
NINTEDANIB MEDIA BACKGROUNDER 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. International treatment guidelines for IPF 1. What is nintedanib? Nintedanib (OFEV a ) is a small molecule
More informationExperience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina
ORIGINAL 131 RAMR 2017;2:131-135 ISSN 1852-236X Correspondence Gabriela Tabaj gabrielatabaj@gmail.com Received: 11.15.2016 Accepted: 02.03.2017 Experience with the Compassionate Use Program of nintedanib
More informationIPF : Dalla Diagnosi alla Terapia
IV Forum di Pneumologia Interventistica Bologna 5-6 Giugno 2015 IPF : Dalla Diagnosi alla Terapia Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale
More information